sign in

Self-Assessment Modules

ID
Test Name
StatusAction
5 Human Prion Diseases

At the end of this module, the participant will be able to:

  1. Describe the role of cellular prion protein in the pathogenesis of prion disease.
  2. Define type 1 and type 2 prion protein
  3. Contrast clinical and histopathologic features of types MM1 and VV2 sporadic Jakob-Creutzfeldt disease.
  4. Define the sensitivity of immunohistochemical staining and immunoblot analysis in the diagnosis of sporadic prion disease.
  5. Describe the histopathology of Gerstmann-Straussler-Scheinker disease and fatal familial insomnia.
  6. Contrast clinical and pathologic features of variant and sporadic prion diseases.
  7. Define clinical and laboratory features of variably protease sensitive prionopathy.
  8. Choose optimal decontamination methods for contaminated instruments, surfaces, and tissues.
Available
(attempts allowed: 3)
Buy ($25.00)
18 Examination of the Clinicopathologic Continuum of Alzheimer Disease in Autopsy Cohort of the National Alzheimer Coordinating Center

The educational design of this activity addresses the needs of physicians and scientist in the field of neuropathology and neurology involved in the diagnosis and/or treatment of patients MCI and AD dementia. This course was certified by AANP for 1.0 hour of AMA PRA Category 1 Credit™ .

After completing this activity, participants should be better able to:

  1. Discuss the pre-mortem clinical and biomarker data to best predict the likelihood of underlying AD pathology
  2. Recognize the varying underlying pathologies that lead to the most likely prediction for the cognitive impairment of AD.
  3. Cite the limitations of generalization of pre-mortem clinical and biomarker status to the prediction of underlying AD pathology.
Available
(attempts allowed: 3)
Buy ($25.00)
25 FGFR1 mutations in Rosette-forming glioneuronal tumors of the fourth ventricle
The educational design of this activity addresses the needs of physicians and scientist in the field of neuropathology and surgical pathology involved in the diagnosis and/or treatment of patients with brain tumors.

After completing this activity, participants should be better able to:
  1. Compare molecular genetic characteristics of rosette-forming glioneuronal tumors (RGNT) and pilocytic astrocytomas.
  2. Estimate the frequency of FGFR1 mutations in RGNT as suggested by the paper.
  3. Discuss clinical and histological correlations of FGFR1 mutations in RGNT.

Available
(attempts allowed: 3)
Buy ($25.00)